NSE ScannerHospitals & Diagnostics · Medical/Nursing Services · NSE: NEPHROPLUS · data 2026-10-31
Nephrocare Health Services Limited
In plain words
Price: 21.4% below its 52-week high of ₹781.5.
Delivery: 49.1% of traded shares were kept for delivery over the last 10 sessions, against 53.9% over the last 60.
Latest results: a net profit of ₹32 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | — |
| Net profit (last 12 months) | — |
| Sales growth, 3 years (yearly) | 31.6% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 58.3%, pledged 0.0%, institutions 19.8%.
ROE 9.0%, ROCE 14.6%: how much profit it earns on the money it uses.
Debt/equity 0.07, Profit growth — and sales growth 31.6% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
NEPHROPLUS Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹281.75 crore, up 6.1% QoQ.
Net profit was ₹31.97 crore, up 5.3% QoQ.
Operating margin was 22.7%.
EPS was ₹3.19, up 5.3% QoQ.
NEPHROPLUS के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹281.75 करोड़; पिछली तिमाही की तुलना में 6.1% की बढ़त।
शुद्ध मुनाफ़ा: ₹31.97 करोड़; पिछली तिमाही की तुलना में 5.3% की बढ़त।
ऑपरेटिंग मार्जिन: 22.7%।
EPS: ₹3.19; पिछली तिमाही की तुलना में 5.3% की बढ़त।
NEPHROPLUSના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹281.75 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 6.1% વધારો.
ચોખ્ખો નફો: ₹31.97 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 5.3% વધારો.
ઓપરેટિંગ માર્જિન: 22.7%.
EPS: ₹3.19; ગયા ક્વાર્ટરની સરખામણીએ 5.3% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
25/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 53.7% over the last 20 sessions vs 58.3% in the 40 before (0.92x); shares delivered per day 0.33x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 17/20: Net +₹120.1 cr bought in bulk/block deals over 90 days (11.89x a usual day's traded value); 1 net buying day, 0 net selling days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 3/15: 2 schemes hold it, about ₹71 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Results
- 24 Sept 26Deal Bulk deal: POLAR CAPITAL FUNDS PLC-HEALTHCARE… bought ₹179.47 cr (net +₹120.1 cr) -6.1% next session
- 11 Aug 26Results Q1 FY27 results: net profit ₹32 cr -2.7% next session
- 19 May 26Results Q4 FY26 results: net profit ₹30.4 cr -4.6% next session
- 10 Feb 26Results Q3 FY26 results: net profit ₹32.2 cr +10.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹282 cr | ₹32 cr | — | 22.7% | 3.19 |
| Mar 2026 | ₹266 cr | ₹30 cr | — | 20.2% | 3.03 |
| Dec 2025 | ₹260 cr | ₹32 cr | — | 23.4% | 3.43 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 58.31% | 63.85% | 63.85% | 63.85% |
| Foreign institutions (FII) | 11.73% | 8.78% | 9.94% | 9.30% |
| Domestic institutions (DII) | 8.11% | 9.05% | 8.65% | 8.10% |
| Mutual funds | 3.93% | 3.20% | 3.17% | 3.10% |
| Retail investors | 6.41% | 3.75% | 3.13% | 3.97% |
| Number of shareholders | 56,735 | 44,091 | 43,409 | 67,416 |
Common questions
What was Nephrocare Health Services Limited's latest quarterly profit?
Nephrocare Health Services Limited reported a net profit of ₹32 cr for the quarter ended Jun 2026, on revenue of ₹282 cr.
How much do promoters hold in Nephrocare Health Services Limited?
Promoters held 58.31% of Nephrocare Health Services Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Nephrocare Health Services Limited debt-free?
Its latest reported debt-to-equity ratio is 0.07, which is very low.
What is the 52-week high and low of Nephrocare Health Services Limited?
The 52-week high is ₹781.5 and the 52-week low is ₹446.
Mutual funds holding Nephrocare Health Services Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 2 schemes holding about ₹71 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 1.12% | ₹66 cr |
| SBI Children's Fund - Investment Plan | SBI Mutual Fund | 0.07% | ₹6 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Nephrocare Health Services Limited | ₹614.55 | ₹6,194 cr | — | — | 9% | 14.6% | 0.07 | +25.4% |
| Vijaya Diagnostic Centre Ltd. | ₹1,445.7 | ₹14,906 cr | 79.5 | — | 19.7% | 19.6% | 0.44 | +43.3% |
| Metropolis Healthcare Ltd. | ₹545.65 | ₹11,309 cr | 56.2 | — | 13.4% | 16.3% | 0.15 | +12.3% |
| Thyrocare Technologies Ltd | ₹456.3 | ₹7,274 cr | 51 | 13.1 | 28.8% | 34.2% | 0.09 | +1.5% |
| Jeena Sikho Lifecare Limited | ₹334.45 | ₹4,149 cr | 17.6 | — | 60% | 62.7% | 0.27 | -54.9% |
| Dr. Agarwal'S Eye Hospital Limited | ₹5,317.5 | ₹2,552 cr | 33.5 | — | 25.2% | 17.4% | 0.94 | +13.1% |
Compare NEPHROPLUS with VIJAYA in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open NEPHROPLUS in NSE Scanner →